Placental growth factor in cancer

Bibliography

• Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 1991;88:9267-71
   PubMed Web of Science ®Google Scholar
• De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012;44:1-9
   PubMed Web of Science ®Google Scholar
• DiPalma T, Tucci M, Russo G, et al. The placenta growth factor gene of the mouse. Mamm Genome 1996;7:6-12
   PubMedGoogle Scholar
• Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-9
   PubMed Web of Science ®Google Scholar
• Migdal M, Huppertz B, Tessler S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998;273:22272-8
   PubMed Web of Science ®Google Scholar
• Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40
   PubMed Web of Science ®Google Scholar
• Hoffmann DC, Willenborg S, Koch M, et al. Proteolytic processing regulates placental growth factor activities. J Biol Chem 2013;288:17976-89
   PubMed Web of Science ®Google Scholar
• Martino MM, Briquez PS, Guc E, et al. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science 2014;343:885-8
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83
   PubMed Web of Science ®Google Scholar
• Tudisco L, Della Ragione F, Tarallo V, et al. Epigenetic control of hypoxia inducible factor-1alpha-dependent expression of placental growth factor in hypoxic conditions. Epigenetics 2014;9:600-10
   PubMed Web of Science ®Google Scholar
• Fischer C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-56
   PubMed Web of Science ®Google Scholar
• Snuderl M, Batista A, Kirkpatrick ND, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 2013;152:1065-76
   PubMed Web of Science ®Google Scholar
• Hedlund EM, Yang X, Zhang Y, et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci USA 2013;110:654-9
   PubMed Web of Science ®Google Scholar
• Loges S, Roncal C, Carmeliet P. Development of targeted angiogenic medicine. J Thromb Haemost 2009;7:21-33
   Google Scholar
• Dewerchin M, Carmeliet P. PlGF: a multitasking cytokine with disease-restricted activity. Cold Spring Harb Perspect Med 2012;2: doi: 10.1101/cshperspect.a011056
   PubMed Web of Science ®Google Scholar
• Kim KJ, Cho CS, Kim WU. Role of placenta growth factor in cancer and inflammation. Exp Mol Med 2012;44:10-19
   PubMed Web of Science ®Google Scholar
• De Falco S. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med 2014;29:1-11
   PubMed Web of Science ®Google Scholar
• Park JE, Chen HH, Winer J, et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994;269:25646-54
   PubMed Web of Science ®Google Scholar
• Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1:1356-70
   PubMed Web of Science ®Google Scholar
• Anisimov A, Leppanen VM, Tvorogov D, et al. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal 2013;6:ra52
   PubMed Web of Science ®Google Scholar
• Cao Y, Linden P, Shima D, et al. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996;98:2507-11
   PubMed Web of Science ®Google Scholar
• DiSalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J Biol Chem 1995;270:7717-23
   PubMed Web of Science ®Google Scholar
• Brave SR, Eberlein C, Shibuya M, et al. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. Angiogenesis 2010;13:337-47
   PubMed Web of Science ®Google Scholar
• Tarallo V, Vesci L, Capasso O, et al. A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 2010;70:1804-13
   PubMed Web of Science ®Google Scholar
• Tarallo V, Tudisco L, De Falco S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am J Cancer Res 2011;1:265-74
   PubMed Web of Science ®Google Scholar
• Cudmore MJ, Hewett PW, Ahmad S, et al. The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun 2012;3:972
   PubMed Web of Science ®Google Scholar
• Roy H, Bhardwaj S, Babu M, et al. Adenovirus-mediated gene transfer of placental growth factor to perivascular tissue induces angiogenesis via upregulation of the expression of endogenous vascular endothelial growth factor-A. Hum Gene Ther 2005;16:1422-8
   PubMed Web of Science ®Google Scholar
• Marcellini M, De Luca N, Riccioni T, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 2006;169:643-54
   PubMed Web of Science ®Google Scholar
• Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003;9:936-43
   PubMed Web of Science ®Google Scholar
• Hagberg CE, Falkevall A, Wang X, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 2010;464:917-21
   PubMed Web of Science ®Google Scholar
• Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002;1:99-108
   PubMed Web of Science ®Google Scholar
• Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 2006;66:3971-7
   PubMed Web of Science ®Google Scholar
• Schomber T, Kopfstein L, Djonov V, et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 2007;67:10840-8
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-38
   PubMed Web of Science ®Google Scholar
• Bagley RG, Ren Y, Weber W, et al. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res 2011;17:976-88
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20:158-63
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang Y, Yang Y, et al. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci USA 2013;110:13932-7
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010;13:16-28
   PubMed Web of Science ®Google Scholar
• Loges S, Schmidt T, Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res 2009;15:3648-53
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-75
   PubMed Web of Science ®Google Scholar
• Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010;141:178-90
   PubMed Web of Science ®Google Scholar
• Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011;19:31-44
   PubMed Web of Science ®Google Scholar
• Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010;141:166-77
   PubMed Web of Science ®Google Scholar
• Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 2011;108:11590-5
   PubMed Web of Science ®Google Scholar
• Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40
   PubMed Web of Science ®Google Scholar
• Wei SC, Tsao PN, Weng MT, et al. Flt-1 in colorectal cancer cells is required for the tumor invasive effect of placental growth factor through a p38-MMP9 pathway. J Biomed Sci 2013;20:39
   PubMed Web of Science ®Google Scholar
• Coenegrachts L, Maes C, Torrekens S, et al. Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res 2010;70:6537-47
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhong Z, Huber J, et al. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006;12:6573-84
   PubMed Web of Science ®Google Scholar
• Taylor AP, Leon E, Goldenberg DM. Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Br J Cancer 2010;103:82-9
   PubMed Web of Science ®Google Scholar
• Zins K, Thomas A, Lucas T, et al. Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts. Int J Mol Sci 2013;14:17958-71
   PubMed Web of Science ®Google Scholar
• Schmidt T, Kharabi Masouleh B, Loges S, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011;19:740-53
   PubMed Web of Science ®Google Scholar
• Schmidt T, Carmeliet P. Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program 2011;2011:1-8
   PubMedGoogle Scholar
• Levati L, Ruffini F, Muzi A, et al. Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-kappaB. Int J Oncol 2011;38:241-7
   PubMed Web of Science ®Google Scholar
• Hedlund EM, Hosaka K, Zhong Z, et al. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci USA 2009;106:17505-10
   PubMed Web of Science ®Google Scholar
• Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009;2:re1
   PubMed Web of Science ®Google Scholar
• Cai J, Wu L, Qi X, et al. Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One 2011;6:e18076
   Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27
   PubMed Web of Science ®Google Scholar
• Heindryckx F, Coulon S, Terrie E, et al. The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model. J Hepatol 2013;58:319-28
   PubMed Web of Science ®Google Scholar
• Laurent J, Faes-Van’t Hull E, Touvrey C, et al. Proangiogenic factor PlGF programs CD11b+ myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res 2011;71:3781-91
   PubMed Web of Science ®Google Scholar
• Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002;62:2749-52
   PubMed Web of Science ®Google Scholar
• Li B, Sharpe EE, Maupin AB, et al. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. Faseb J 2006;20:1495-7
   PubMed Web of Science ®Google Scholar
• Taylor AP, Rodriguez M, Adams K, et al. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003;105:158-64
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51
   PubMed Web of Science ®Google Scholar
• MacDonald N. Chronic inflammatory states: their relationship to cancer prognosis and symptoms. J R Coll Physicians Edinb 2011;41:246-53
   PubMedGoogle Scholar
• Kerber M, Reiss Y, Wickersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008;68:7342-51
   PubMed Web of Science ®Google Scholar
• Ding Y, Huang Y, Song N, et al. NFAT1 mediates placental growth factor-induced myelomonocytic cell recruitment via the induction of TNF-alpha. J Immunol 2010;184:2593-601
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-56
   PubMed Web of Science ®Google Scholar
• Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46
   PubMed Web of Science ®Google Scholar
• De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Garlanda C, Jaillon S, et al. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013;228:1404-12
   PubMed Web of Science ®Google Scholar
• Jetten N, Verbruggen S, Gijbels MJ, et al. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014;17:109-18
   PubMed Web of Science ®Google Scholar
• Gao F, Liang B, Reddy ST, et al. Role of inflammation-associated microenvironment in tumorigenesis and metastasis. Curr Cancer Drug Targets 2014;14:30-45
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, et al. Reply. Nature 2009;461:E5-6
   Google Scholar
• Dawson MR, Duda DG, Fukumura D, et al. VEGFR1-activity-independent metastasis formation. Nature 2009;461:E4; discussion E5
   PubMed Web of Science ®Google Scholar
• Dawson MR, Duda DG, Chae SS, et al. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One 2009;4:e6525
   PubMed Web of Science ®Google Scholar
• Duda DG, Jain RK. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Res 2010;70:5670-3
   PubMed Web of Science ®Google Scholar
• Van Steenkiste C, Ribera J, Geerts A, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011;53:1629-40
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Corlu A, Glaise D, et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012;72:2533-42
   PubMed Web of Science ®Google Scholar
• Jain RK, Xu L. alphaPlGF: a new kid on the antiangiogenesis block. Cell 2007;131:443-5
   PubMed Web of Science ®Google Scholar
• Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007;6:524-31
   PubMed Web of Science ®Google Scholar
• Heindryckx F, Bogaerts E, Coulon SH, et al. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model. Eur J Gastroenterol Hepatol 2012;24:1020-32
   PubMed Web of Science ®Google Scholar
• Oude Munnink TH, Tamas KR, Lub-de Hooge MN, et al. Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441. J Nucl Med 2013;54:929-35
   PubMed Web of Science ®Google Scholar
• Li F, Su P, Lin C, et al. Ribosome display and selection of human anti-placental growth factor scFv derived from ovarian cancer patients. Protein Pept Lett 2010;17:585-90
   PubMed Web of Science ®Google Scholar
• Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996;226:324-8
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res 2013;19:1920-5
   PubMed Web of Science ®Google Scholar
• Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol 2013;4:231-8
   PubMedGoogle Scholar
• Colombo N, Mangili G, Mammoliti S, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 2012;125:42-7
   PubMed Web of Science ®Google Scholar
• Glade Bender J, Blaney SM, Borinstein S, et al. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children’s oncology group phase I consortium report. Clin Cancer Res 2012;18:5081-9
   PubMed Web of Science ®Google Scholar
• Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics 2014;8:13-25
   PubMedGoogle Scholar
• Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2014; Epub 2014/04/29
   Google Scholar
• Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403: a first-in-human, Phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther 2011;33:1142-9
   PubMed Web of Science ®Google Scholar
• Rizzo C, Yin Xin X, Packman K, et al. RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC Philadelphia (PA): AACR. Cancer Res 2010;70(8 Suppl):abstract no 1370
   Google Scholar
• Nielsen DL, Sengelov L. Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Expert Opin Biol Ther 2012;12:795-804
   PubMed Web of Science ®Google Scholar
• Lassen U, Nielsen DL, Sorensen M, et al. A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer 2012;106:678-84
   PubMed Web of Science ®Google Scholar
• Lassen UN, Chinot OL, McBain C, et al. Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mAb bevacizumab (BV) in patients with recurrent glioblastoma (GBM). J Clin Oncol 2013;31(Suppl):abstract 2092
   Google Scholar
• Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301
   PubMed Web of Science ®Google Scholar
• Harris AL, Reusch P, Barleon B, et al. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7:1992-7
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Yoshida T, Akiyoshi J, et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 2010;23:1647-54
   PubMed Web of Science ®Google Scholar
• Coenegrachts L, Schrauwen S, Van Bree R, et al. Increased expression of placental growth factor in high-grade endometrial carcinoma. Oncol Rep 2013;29:413-18
   PubMed Web of Science ®Google Scholar
• Chen CN, Hsieh FJ, Cheng YM, et al. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004;213:73-82
   PubMed Web of Science ®Google Scholar
• Escudero-Esparza A, Martin TA, Davies ML, et al. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 2009;6:239-46
   PubMedGoogle Scholar
• Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005;54:666-72
   PubMed Web of Science ®Google Scholar
• Gomceli I, Tez M, Bostanci EB, et al. Is serum placental growth factor a prognostic marker for stage III colorectal cancer patients? Hepatogastroenterology 2012;59:1437-40
   PubMedGoogle Scholar
• Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003;23:4953-8
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Schmidt T, Falk CS, et al. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 2011;11:286
   PubMed Web of Science ®Google Scholar
• Xu HX, Zhu XD, Zhuang PY, et al. Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer 2011;128:1559-69
   PubMed Web of Science ®Google Scholar
• Ho MC, Chen CN, Lee H, et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007;250:237-49
   PubMed Web of Science ®Google Scholar
• Rahbari NN, Reissfelder C, Muhlbayer M, et al. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases. Ann Surg Oncol 2011;18:2182-91
   PubMed Web of Science ®Google Scholar
• Escudero-Esparza A, Martin TA, Douglas-Jones A, et al. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance. Oncol Rep 2010;23:537-44
   PubMed Web of Science ®Google Scholar
• Parr C, Watkins G, Boulton M, et al. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005;41:2819-27
   PubMed Web of Science ®Google Scholar
• Maae E, Olsen DA, Steffensen KD, et al. Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. Breast Cancer Res Treat 2012;133:257-65
   PubMed Web of Science ®Google Scholar
• Li B, Wang C, Zhang Y, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 2013;32:2952-62
   PubMed Web of Science ®Google Scholar
• Zhang L, Chen J, Ke Y, et al. Expression of Placenta growth factor (PlGF) in non-small cell lung cancer (NSCLC) and the clinical and prognostic significance. World J Surg Oncol 2005;3:68
   PubMedGoogle Scholar
• Cheng SJ, Lee JJ, Kok SH, et al. Expression of placenta growth factor: an independent factor for prediction of progression and prognosis of oral cancer. Head Neck 2010;32:1363-9
   PubMed Web of Science ®Google Scholar
• Cheng SJ, Cheng SL, Lee JJ, et al. Increased placenta growth factor mRNA level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma. J Formos Med Assoc 2013;112:253-8
   PubMed Web of Science ®Google Scholar
• Hilfenhaus G, Gohrig A, Pape UF, et al. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. Endocr Relat Cancer 2013;20:305-19
   PubMed Web of Science ®Google Scholar
• Ilhan-Mutlu A, Wagner L, Widhalm G, et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev 2013;36:45-55
   PubMed Web of Science ®Google Scholar
• Sujka-Kordowska P, Malinska A, Ostalska-Nowicka D, et al. CD105 and placental growth factor – potent prognostic factors in childhood acute lymphoblastic leukaemia. Leuk Res 2012;36:846-51
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Penson RT, Duda DG, et al. Safety, efficacy, and biomarker exploration in a phase II study of bevacizumab, oxaliplatin, and gemcitabine in recurrent mullerian carcinoma. Clin Ovarian Cancer Other Gynecol Malig 2011;4:26-33
   PubMedGoogle Scholar
• Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-9
   PubMed Web of Science ®Google Scholar
• Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One 2013;8:e77117
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Fioravanti A, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104:1262-9
   PubMed Web of Science ®Google Scholar
• Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-8
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013;19:6614-23
   PubMed Web of Science ®Google Scholar
• Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-35
   PubMed Web of Science ®Google Scholar
• Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 2013;19:1557-66
   PubMed Web of Science ®Google Scholar
• Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012;17:1063-72
   PubMed Web of Science ®Google Scholar
• Hamberg P, Boers-Sonderen MJ, van der Graaf WT, et al. Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer 2014;110:888-93
   PubMed Web of Science ®Google Scholar
• Uronis HE, Cushman SM, Bendell JC, et al. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Med 2013;2:316-24
   PubMed Web of Science ®Google Scholar
• Bass MB, Sherman SI, Schlumberger MJ, et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010;95:5018-27
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95
   PubMed Web of Science ®Google Scholar
• de Groot JF, Piao Y, Tran H, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res 2011;17:4872-81
   PubMed Web of Science ®Google Scholar
• Kim KB, Chesney J, Robinson D, et al. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 2011;17:7451-61
   PubMed Web of Science ®Google Scholar
• Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995;11:1569-79
   PubMed Web of Science ®Google Scholar
• Sowter HM, Corps AN, Evans AL, et al. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Invest 1997;77:607-14
   PubMed Web of Science ®Google Scholar
• Xu L, Jain RK. Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. Mol Cancer Res 2007;5:873-80
   Google Scholar
• Hatva E, Bohling T, Jaaskelainen J, et al. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 1996;148:763-75
   PubMed Web of Science ®Google Scholar